Tumor-Infiltrating Lymphocytes (TILs) Isolation with Microfluidic-Capture Microdissection (MCM) System
The SACA system, which utilizes a variety of technology including a dynamic Live- cell Staining Microdialysis Chip and Patient-Derive Explants Platform used for profiling, allows for more efficient response assessment and selection for cancer immunotherapy. We developed a Microfluidic-capture Microdissection (MCM) system for single cell isolation based on nondestructive sampling, providing highly customized & quality total solutions to procure subpopulations of live tissue cells or PMBC in blood.
Targeted indication
Cancer Immune-cell Therapy
Status
Prototype platform of Microfluidic-capture Microdissection (MCM) for validation of the possibility of therapeutic tumor- infiltrating lymphocytes (TILs) isolation can cultured
Key features
- Without of flow cytometry & magnetic beads selection
- Therapeutic tumor-infiltrating lymphocytes (TILs) be isolated from tumor tissue or circulating tumor microemboli(CTM)
- Identification of neoantigen-specific T cells in PBMC
Market
MODE OF ACTION
EXPERIMENTAL RESULTS
Proof of IEC61010-1 &61326-1
In clinical performance study with Shin Kong Wu Ho-Su Memorial Hospital
Plan to start the clinical trials (pivotal studies) at 2024 Q3
On the way of building up the SOP of time-reducing DC-CIK processing that ruled by regulation governing specific cellular therapeutic technology
INTELLECTUAL PROPERTY
SELECTED PUBLICATIONS
17+ Journal papers
BUSINESS OPPORTUNITY
✓ Long-term culture and pretreatment processing of DC-CIK.
✓ Low specific for solid tumor.
✓ Poor clinical outcome.
✓ Co-development with strategy partners are focused on Driving T-cell immunotherapy or CAR-T to solid tumors.
CONTACT
service@biip-dcc.org